It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Our chemists work collaboratively as true partners, guiding you through the complexities of drug discovery and ensuring the most strategic route to clinical success.
Adapting to your goals and challenges, we apply a flexible, hypothesis driven approach to tailor each program to your specific requirements. Through efficient screening cascades, rapid data generation, and expert interpretation, we balance agility with scientific rigor to accelerate discovery and maximize value.
Advance your path to the clinic with an integrated approach that brings together medicinal chemistry, innovative synthetic chemistry design, computation, bioscience, and DMPK expertise. We design, optimize, and deliver breakthrough molecules with agility and precision – always aligned with your program’s objectives.
Medicinal Chemistry Expertise
Rapid SAR Exploration
Fast access to diverse compounds through library synthesis and scaffold design enables efficient structure-activity relationship evaluation.
Data-Driven Decision Making
Expert analysis using Reaxys, Dotmatics and Votrex supports informed target selection and optimized synthetic strategies.
Early ADMET Insight
Integrated assessment and monitoring of ADMET properties lead to smarter design decisions and higher-quality candidates.
Key Strengths
At Sygnature Discovery, strength comes from experience, collaboration, and innovation. Our medicinal chemists combine scientific depth, agility, and advanced technology to design and deliver molecules that meet your goals and move discovery confidently toward the clinic.
Medicinal Chemistry Expertise
Our teams design drug-like molecules, integrate seamlessly with biology, and span modalities – from small molecules to ADCs – driving discovery forward with speed and confidence.
Design Excellence and Delivery
From hit to candidate, we combine creativity, efficiency, and scientific rigor to deliver molecules ready for clinical assessment.
True Scientific Partnership
We communicate openly, share our rationale, and provide solutions that support confident decision-making throughout the design–make–test–analyze cycle.
Flexible and Cross-Disciplinary
Whether embedded in integrated teams or working alongside your internal scientists, we have the breadth of experience, practical knowhow and experts working in all therapeutic areas and modalities.
Deep Experience, Proven Outcomes
Decades of collective success bringing compounds to the clinic through precise design, efficient synthesis, and an unwavering focus on value.
Efficiency Through Innovation
Constantly evolving capabilities, bringing the latest literature, automation, and data insight into our labs to accelerate make–test–decide cycles.
Empowered by People and Culture
A community of drug hunters united by curiosity, transparency, and a shared goal: transforming ideas into patient impact.
Empowered by Modern Tools and Computational Insight
Human Expertise, Enhanced by Technology
Our medicinal chemists work hand in hand with Computational Chemistry and CADD teams, using AI-assisted design, predictive modeling, and retrosynthetic analysis to strengthen decisions and accelerate progress.
Proprietary platforms such as SygDesign enable hypothesis testing and molecular optimization, while our IDEA Tracker ensures full transparency across the DMTA cycle. Every design decision is traceable, data-driven, and aligned with your goals.
Innovation that Drives Results
By combining deep medicinal chemistry expertise with AI, data analytics, and automation, we deliver reproducible science that stands up to clinic scrutiny- turning design efficiency into measurable discovery impact.
Why Choose Sygnature Discovery for Medicinal Chemistry Support?
Because partnership, transparency, and science excellence drive every decision. Our chemists combine creativity with efficiency, communicating solutions clearly and openly. Supported by AI-enhanced design and integrated expertise across modalities and scales, we deliver data-driven, clinically focused chemistry that moves your discovery forward with you always in control.
Yixin Cui, Alice Lanne, Sreenivas Avula, Mariwan A Hama Salih, Xudan Peng, Gavin Milne,…
Journal Papers
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Creative, scalable synthetic chemistry solutions using modern methodologies and advanced tools, transforming complex challenges into efficient, high-quality outcomes.
Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
